Leukemia Research
Volume 29, Issue 7 , Pages 803-812 , July 2005

Wt1 is not essential for hematopoiesis in the mouse

  • Linda King-Underwood

      Affiliations

    • Section of Paediatric Oncology, Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    • ,
  • Suzanne Little

      Affiliations

    • Section of Paediatric Oncology, Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    • ,
  • Mandy Baker

      Affiliations

    • Section of Paediatric Oncology, Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    • ,
  • Robyn Clutterbuck

      Affiliations

    • Section of Paediatric Oncology, Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    • ,
  • Sylvie Delassus

      Affiliations

    • Section of Gene Function and Regulation, Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    • ,
  • Tariq Enver

      Affiliations

    • Section of Gene Function and Regulation, Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    • ,
  • Clive Lebozer

      Affiliations

    • Biological Services Unit, Institute of Cancer Research, Sutton, Surrey, UK
    • ,
  • Toon Min

      Affiliations

    • Academic Haematology and Cytogenetics, Royal Marsden NHS Trust, Sutton, Surrey, UK
    • ,
  • Adrian Moore

      Affiliations

    • MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK
    • ,
  • Andreas Schedl

      Affiliations

    • MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK
    • ,
  • Kathy Pritchard-Jones

      Affiliations

    • Section of Paediatric Oncology, Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    • Corresponding Author InformationCorresponding author. Present address: Paediatric Oncology, Paediatric Department, The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. Tel.: +44 20 8661 3453; fax: +44 20 8661 3617.

Received 3 June 2004 ,Accepted 26 November 2004.

References 

  1. Hastie ND. The genetics of Wilms’ tumor: a case of disrupted development. Annu Rev Genet. 1994;28:523–558
  2. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res. 2001;264(1):74–99
  3. Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, et al. The candidate Wilms’ tumour gene is involved in genitourinary development. Nature. 1990;346(6280):194–197
  4. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89(4):1405–1412
  5. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms’ tumor gene WT1 in leukemias. Blood. 1996;87(6):2171–2179
  6. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms’ tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol. 1997;25(9):945–950
  7. Baird PN, Simmons PJ. Expression of the Wilms’ tumor gene (WT1) in normal hemopoiesis. Exp Hematol. 1997;25(4):312–320
  8. Fraizer GC, Patmasiriwat P, Zhang X, Saunders GF. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow (Letter). Blood. 1995;86(12):4704–4706
  9. Pritchard-Jones K, King-Underwood L. The Wilms tumour gene WT1 in leukaemia. Leuk Lymph. 1997;27(3–4):207–220
  10. King-Underwood L, Pritchard-Jones K. Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 1998;91(8):2961–2968
  11. Miyagawa K, Hayashi Y, Fukuda T, Mitani K, Hirai H, Kamiya K. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Genes Chromosomes Cancer. 1999;25(2):176–183
  12. Deuel TF, Guan LS, Wang ZY. Wilms’ tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain. Biochem Biophys Res Commun. 1999;254(1):192–196
  13. Carrington D, Algar E. Overexpression of murine WT1 +/+ and −/− isoforms has no effect on chemoresistance but delays differentiation in the K562 leukemia cell line. Leuk Res. 2000;24(11):927–936
  14. Svedberg H, Chylicki K, Baldetorp B, Rauscher F, Gullberg U. Constitutive expression of the Wilms’ tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. Oncogene. 1998;16(7):925–932
  15. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, et al. Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood. 1998;91(8):2969–2976
  16. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y, et al. Constitutive expression of the Wilms’ tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res. 1999;23(5):499–505
  17. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84(9):3071–3079
  18. Reddy JC, Licht JD. The WT1 Wilms’ tumor suppressor gene: how much do we really know?. Biochim Biophys Acta. 1996;1287(1):1–28
  19. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001;20(8):1897–1909
  20. Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher FJ. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms’ tumor locus. J Biol Chem. 1993;268(28):21271–21275
  21. Zhang X, Fraizer G, Saunders G. Two hematopoietic specific enhancers of the WT1 gene function in different cell lineages. Blood. 1995;86(10S1):2980;[Abstract number]
  22. Fraizer GC, Wu YJ, Hewitt SM, Maity T, Ton CC, Huff V, et al. Transcriptional regulation of the human Wilms’ tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. J Biol Chem. 1994;269(12):8892–8900
  23. Renshaw J, King-Underwood L, Pritchard-Jones K. Differential splicing of exon 5 of the Wilms tumour (WTI) gene. Genes Chromosomes Cancer. 1997;19(4):256–266
  24. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, et al. WT1 is required for early kidney development. Cell. 1993;74(4):679–691
  25. Herzer U, Crocoll A, Barton D, Howells N, Englert C. The Wilms tumor suppressor gene wt1 is required for development of the spleen. Curr Biol. 1999;9(15):837–840
  26. Moore AW, Schedl A, McInnes L, Doyle M, Hecksher-Sorensen J, Hastie ND. YAC transgenic analysis reveals Wilms’ Tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. Mech Dev. 1998;79(1–2):169–184
  27. Moore AW, McInnes L, Kreidberg J, Hastie ND, Schedl A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development. 1999;126(9):1845–1857
  28. Sanchez MJ, Holmes A, Miles C, Dzierzak E. Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo. Immunity. 1996;5(6):513–525
  29. Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL. The purification and characterization of fetal liver hematopoietic stem cells. Proc Natl Acad Sci USA. 1995;92(22):10302–10306
  30. MacGregor GR, Nolan GP, Fiering S, Roederer M, Herzenberg LA. Use of E. coli lacZ (b-Galactosidase) as a reporter gene. In:  Murray EJ editors. Methods in molecular biology, gene transfer and expression protocols. vol. 7:Clifton, NJ: The Humana Press Inc.; 1991;p. 217–228
  31. Naylor S, Smalley MJ, Robertson D, Gusterson BA, Edwards PA, Dale TC. Retroviral expression of Wnt-1 and Wnt-7b produces different effects in mouse mammary epithelium. J Cell Sci. 2000;113(Pt 12):2129–2138
  32. Little MH, Dunn R, Byrne JA, Seawright A, Smith PJ, Pritchard-Jones K, et al. Equivalent expression of paternally and maternally inherited WT1 alleles in normal fetal tissue and Wilms’ tumours. Oncogene. 1992;7(4):635–641
  33. Delassus S, Titley I, Enver T. Functional and molecular analysis of hematopoietic progenitors derived from the aorta-gonad-mesonephros region of the mouse embryo. Blood. 1999;94(5):1495–1503
  34. Delassus S, Cumano A. Circulation of hematopoietic progenitors in the mouse embryo. Immunity. 1996;4(1):97–106
  35. Muhlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer. 1998;21(2):90–100
  36. Moore AW. Transgenic analysis of the Wilms’ tumour 1 (WT1) expression and regulation. Ph.D. Thesis, University of Edinburgh; 1997.
  37. Kreidberg JA, Natoli TA, McGinnis L, Donovan M, Biggers JD, Amstutz A. Coordinate action of Wt1 and a modifier gene supports embryonic survival in the oviduct. Mol Reprod Dev. 1999;52(4):366–375
  38. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JB. The expression of the Wilms’ tumour gene, WT1, in the developing mammalian embryo. Mech Dev. 1993;40(1–2):85–97
  39. Alberta JA, Springett GM, Rayburn H, Natoli TA, Loring J, Kreidberg JA, et al. Role of the WT1 tumor suppressor in murine hematopoiesis. Blood. 2003;101(7):2570–2574
  40. Murata Y, Kudoh T, Sugiyama H, Toyoshima K, Akiyama T. The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. FEBS Lett. 1997;409(1):41–45
  41. Phelan SA, Lindberg C, Call KM. Wilms’ tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ. 1994;5(6):677–686
  42. Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A. Downregulation of Wilms’ tumor gene (Wt1) during myelomonocytic differentiation in HL60 cells. Blood. 1994;83(7):1876–1882
  43. Smith SI, Weil D, Johnson GR, Boyd AW, Li CL. Expression of the Wilms’ tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. Blood. 1998;91(3):764–773
  44. Svedberg H, Chylicki K, Gullberg U. Downregulation of Wilms’ tumor gene (WT1) is not a prerequisite for erythroid or megakaryocytic differentiation of the leukemic cell line K562. Exp Hematol. 1999;27(6):1057–1062
  45. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 2000;287(5459):1804–1808
  46. Svedberg H, Richter J, Gullberg U. Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells. Leukemia. 2001;15(12):1914–1922
  47. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene. 1996;12(5):1005–1014
  48. Yamagami T, Ogawa H, Tamaki H, Oji Y, Soma T, Oka Y, et al. Suppression of Wilms’ tumor gene (WT1) expression induces G2/M arrest in leukemic cells. Leuk Res. 1998;22(4):383–384
  49. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87(7):2878–2884

PII: S0145-2126(05)00033-0

doi: 10.1016/j.leukres.2004.11.020

Leukemia Research
Volume 29, Issue 7 , Pages 803-812 , July 2005

Article Tools

* Image Usage & Resolution